Meridian Bioscience Inc.
Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid immunoassay under the ImmunoCard and ImmunoCard STAT! brands; enzyme-linked immunoassays under the PREMIER brand; anodic stripping voltammetry under the LeadCare and PediaStat brands; and urea breath testing for H. pylori under the BreathID brand. This segment also offers gastrointestinal assays, including tests for C. difficile, H. pylori, and certain foodborne pathogens; respiratory illness assays, such as tests Group A strep, mycoplasma pneumonia, influenza, and pertussis; and blood chemistry assays for testing elevated levels of lead in blood. It sells products through direct sales force and independent distributors to acute care hospitals, reference laboratories, outpatient clinics, and physician office laboratories. The Life Science segment offers bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, and bioresearch reagents used by in vitro diagnostic manufacturers, as well as researchers in immunological and molecular tests for human, animal, plant, and environmental applications. The company has a strategic collaboration with DiaSorin Inc. to sell H. pylori tests. Meridian Bioscience, Inc. was incorporated in 1976 and is headquartered in Cincinnati, Ohio.
IPO Year: 1986
Exchange: NASDAQ
Website: meridianbioscience.com
Peers
Recent Analyst Ratings for Meridian Bioscience Inc.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/7/2022 | $28.00 → $30.00 | Buy | HC Wainwright & Co. |
| 11/15/2021 | $27.00 → $28.00 | Buy | HC Wainwright & Co. |
| 8/9/2021 | $30.00 → $27.00 | Buy | HC Wainwright & Co. |
Meridian Bioscience Inc. Press Releases
Fastest customizable press release news feed in the world
SD Biosensor and SJL Partners Complete Transaction to Acquire Meridian Bioscience
CINCINNATI and SEOUL, South Korea, Jan. 31, 2023 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ:VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, and SD Biosensor, Inc. ("SDB") (KOSE: A137310) and SJL Partners LLC ("SJL") (collectively, the "Consortium"), announced today that they have completed the transaction to acquire Meridian. Under the terms of the merger, Meridian shareholders have the right to receive $34.00 per share in cash. Meridian stock will no longer be traded on the NASDAQ Global Select Market. Meridian will cont
DoubleVerify Holdings to Join S&P SmallCap 600
NEW YORK, Jan. 25, 2023 /PRNewswire/ -- DoubleVerify Holdings Inc. (NYSE:DV) will replace Meridian Bioscience Inc. (NASD: VIVO) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, January 31. SD Biosensor is acquiring Meridian Bioscience in a deal expected to be completed soon pending final conditions. Following is a summary of the change that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector January 31, 2023 S&P SmallCap 600 Addition DoubleVerify Holdings DV Inf
Meridian Bioscience Announces Anticipated Closing Date of the Pending Merger
CINCINNATI, Dec. 12, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ:VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced that it has entered into a side letter with the buyer, setting the closing date of Meridian's pending merger for January 31, 2023. As previously disclosed, on July 7, 2022, Meridian, entered into an Agreement and Plan of Merger (the "Merger Agreement") with SD Biosensor, Inc., ("SDB"), Columbus Holding Company ("Parent"), and Madeira Acquisition Corp., a direct wholly owned subsidiary of Parent ("
MERIDIAN BIOSCIENCE REPORTS FOURTH QUARTER AND FULL YEAR FISCAL 2022 OPERATING RESULTS
CINCINNATI, Nov. 22, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced financial results for the fourth quarter and fiscal year ended September 30, 2022. Fourth Quarter 2022 Highlights (Comparison to Fourth Quarter Fiscal 2021): Consolidated net revenues totaled $65.7 million, a decrease of 14% year-over-yearDiagnostics segment net revenues increased 14% year-over-year to $39.2 millionLife Science segment delivered net revenues of $26.5 million, a decrease of 37%Submitted 510(k) for Curian® Shiga Toxin assayFull Fiscal Year 2022 Highlights (Compariso
MERIDIAN BIOSCIENCE REPORTS THIRD QUARTER FISCAL 2022 OPERATING RESULTS
CINCINNATI, Aug. 5, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced financial results for the third quarter ended June 30, 2022. Third Quarter Fiscal 2022 Highlights (Comparison to Third Quarter Fiscal 2021): Consolidated net revenues totaled $67.8 million, an increase of 7% year-over-yearDiagnostics segment net revenues increased 36% year-over-year to a record $42.4 millionLife Science segment delivered net revenues of $25.4 million, a decrease of 22%Third Quarter Fiscal 2022 Results (Comparison to Third Quarter Fiscal 2021)Consolidated net revenu
Meridian Bioscience Receives Re-Authorization from FDA for its Revogene® SARS-CoV-2 Molecular Assay
CINCINNATI, July 29, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ:VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced that it received re-authorization of its Emergency Use Authorization (EUA) for the Revogene® SARS-COV-2 molecular assay from the U.S. Food and Drug Administration (FDA). Meridian expects to begin shipping this product before the end of its fiscal fourth quarter, ending September 30, 2022. On November 10, 2021, Meridian announced the Revogene® SARS-CoV-2 assay was granted authorization by the FDA.
Meridian Bioscience, Inc. Enters into Agreement to Be Acquired by SD Biosensor and SJL Partners in $1.53 Billion All-Cash Transaction
Shareholders to Receive $34.00 Per Share in Cash, Providing Immediate, Compelling and Certain Value Transaction Follows Deliberate Review, Including Outreach to Potential Strategic and Financial Partners CINCINNATI and SEOUL, South Korea, July 7, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. ("Meridian" or the "Company") (NASDAQ:VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, and SD Biosensor, Inc. ("SDB") (KOSE: A137310) and SJL Partners LLC ("SJL") (collectively, the "Consortium") announced today that they have entered into a definitive merger agreement whereby a newly formed affiliate vehicle of the Consortium will acquire Meridian in an a
Meridian Bioscience Announces Preliminary Results for Fiscal 2022 Third Quarter
CINCINNATI, July 7, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. ("Meridian" or the "Company") (NASDAQ:VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, today provided preliminary results for its third quarter of fiscal 2022. For the third quarter of fiscal 2022, preliminary unaudited net revenues are expected to be between $66 million and $69 million. The Diagnostics segment net revenues are expected to be between $41 million and $43 million. The Life Science segment net revenues are expected to be between $25 million and $26 m
Meridian Launches New qPCR Master Mixes for Stool Samples to Accelerate Development of Molecular Assays
CINCINNATI, June 20, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ:VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today two new sample-specific master mixes, Lyo-Ready™ Direct DNA qPCR Stool Mix, and Lyo-Ready™ Direct RNA/DNA qPCR Stool Mix. These innovative master mixes improve the molecular detection of DNA and RNA from crude fecal specimens while allowing room temperature stabilization of diagnostic assays. Stool samples are used in many gastrointestinal diagnostic tests to screen for harmful bacteria, fun
Meridian Bioscience responds to the Monkeypox Outbreak with its Inhibitor-Tolerant qPCR Master Mixes for the Development of Molecular Tests
CINCINNATI, May 26, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ:VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that its inhibitor-tolerant qPCR master mixes are ideal for the development of fast, accurate and highly sensitive qPCR monkeypox virus (monkeypox) molecular diagnostic tests. The recent outbreak of monkeypox has caused global concern due to its unprecedented rapid spread, resulting in what is feared to be the largest outbreak outside of Africa. Monkeypox is an orthopoxvirus first identified
Meridian Bioscience Inc. Analyst Ratings
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
HC Wainwright & Co. reiterated coverage on Meridian Bioscience with a new price target
HC Wainwright & Co. reiterated coverage of Meridian Bioscience with a rating of Buy and set a new price target of $30.00 from $28.00 previously
HC Wainwright & Co. reiterated coverage on Meridian Bioscience with a new price target
HC Wainwright & Co. reiterated coverage of Meridian Bioscience with a rating of Buy and set a new price target of $28.00 from $27.00 previously
HC Wainwright & Co. reiterated coverage on Meridian Bioscience with a new price target
HC Wainwright & Co. reiterated coverage of Meridian Bioscience with a rating of Buy and set a new price target of $27.00 from $30.00 previously
HC Wainwright & Co. reiterated coverage on Meridian Bioscience with a new price target
HC Wainwright & Co. reiterated coverage of Meridian Bioscience with a rating of Buy and set a new price target of $30.00 from $32.00 previously
HC Wainwright reiterated coverage on Meridian Bioscience with a new price target
HC Wainwright reiterated coverage of Meridian Bioscience with a rating of Buy and set a new price target of $32.00 from $34.00 previously
HC Wainwright & Co. reiterated coverage on Meridian Bioscience with a new price target
HC Wainwright & Co. reiterated coverage of Meridian Bioscience with a rating of Buy and set a new price target of $32.00 from $34.00 previously
Piper Sandler resumed coverage on Meridian Bioscience with a new price target
Piper Sandler resumed coverage of Meridian Bioscience with a rating of Overweight and set a new price target of $34.00 from $26.00 previously
HC Wainwright & Co. reiterated coverage on Meridian Bioscience with a new price target
HC Wainwright & Co. reiterated coverage of Meridian Bioscience with a rating of Buy and set a new price target of $34.00 from $30.00 previously
Meridian Bioscience Inc. Insider Trading
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
SEC Form 4: Williams Felicia returned 10,274 shares to the company, closing all direct ownership in the company
4 - MERIDIAN BIOSCIENCE INC (0000794172) (Issuer)
SEC Form 4: Sazdanoff Catherine returned 16,424 shares to the company, closing all direct ownership in the company
4 - MERIDIAN BIOSCIENCE INC (0000794172) (Issuer)
SEC Form 4: Rice John Mccune Jr. returned 27,449 shares to the company, closing all direct ownership in the company
4 - MERIDIAN BIOSCIENCE INC (0000794172) (Issuer)
SEC Form 4: Mcilwraith John returned 21,724 shares to the company, closing all direct ownership in the company
4 - MERIDIAN BIOSCIENCE INC (0000794172) (Issuer)
SEC Form 4: Ellingwood Dwight E returned 17,290 shares to the company, closing all direct ownership in the company
4 - MERIDIAN BIOSCIENCE INC (0000794172) (Issuer)
SEC Form 4: Bihl Anthony P Iii returned 15,408 shares to the company, closing all direct ownership in the company
4 - MERIDIAN BIOSCIENCE INC (0000794172) (Issuer)
SEC Form 4: Anderson James M. returned 33,224 shares to the company, closing all direct ownership in the company
4 - MERIDIAN BIOSCIENCE INC (0000794172) (Issuer)
SEC Form 4: Kenny John P. was granted 47,060 shares and returned 267,651 shares to the company, closing all direct ownership in the company
4 - MERIDIAN BIOSCIENCE INC (0000794172) (Issuer)
SEC Form 4: Kitzmiller Andrew S. was granted 7,945 shares and returned 19,473 shares to the company, closing all direct ownership in the company
4 - MERIDIAN BIOSCIENCE INC (0000794172) (Issuer)
SEC Form 4: Weltzien Lourdes was granted 7,945 shares and returned 86,045 shares to the company, closing all direct ownership in the company
4 - MERIDIAN BIOSCIENCE INC (0000794172) (Issuer)
Meridian Bioscience Inc. SEC Filings
SEC Form 15-12G filed by Meridian Bioscience Inc.
15-12G - MERIDIAN BIOSCIENCE INC (0000794172) (Filer)
SEC Form 10-Q filed by Meridian Bioscience Inc.
10-Q - MERIDIAN BIOSCIENCE INC (0000794172) (Filer)
SEC Form EFFECT filed by Meridian Bioscience Inc.
EFFECT - MERIDIAN BIOSCIENCE INC (0000794172) (Filer)
SEC Form EFFECT filed by Meridian Bioscience Inc.
EFFECT - MERIDIAN BIOSCIENCE INC (0000794172) (Filer)
SEC Form EFFECT filed by Meridian Bioscience Inc.
EFFECT - MERIDIAN BIOSCIENCE INC (0000794172) (Filer)
SEC Form EFFECT filed by Meridian Bioscience Inc.
EFFECT - MERIDIAN BIOSCIENCE INC (0000794172) (Filer)
SEC Form EFFECT filed by Meridian Bioscience Inc.
EFFECT - MERIDIAN BIOSCIENCE INC (0000794172) (Filer)
SEC Form S-8 POS filed by Meridian Bioscience Inc.
S-8 POS - MERIDIAN BIOSCIENCE INC (0000794172) (Filer)
SEC Form S-8 POS filed by Meridian Bioscience Inc.
S-8 POS - MERIDIAN BIOSCIENCE INC (0000794172) (Filer)
SEC Form S-8 POS filed by Meridian Bioscience Inc.
S-8 POS - MERIDIAN BIOSCIENCE INC (0000794172) (Filer)
Meridian Bioscience Inc. FDA approvals
Live FDA approvals issued by the Food and Drug Administration and FDA breaking news
December 10, 2021 - Coronavirus (COVID-19) Update: December 10, 2021
For Immediate Release: December 10, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: On December 9, 2021, the FDA updated the SARS-CoV-2 Viral Mutations: Impact on COVID-19 Tests web page to share the latest information. The update added new information about the Meridian Bioscience, Inc. Revogene SARS-CoV-2 test, inc
Meridian Bioscience Inc. Leadership Updates
Live Leadership Updates
Meridian Bioscience Announces Retirement of CFO Bryan Baldasare
CINCINNATI, Dec. 2, 2021 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ:VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that Bryan Baldasare, Executive Vice President, Chief Financial Officer, and Secretary, will retire from Meridian effective December 31, 2021. The Company is engaging an executive search firm in the recruitment of a new chief financial officer. The Company appointed Julie Smith to the position of Senior Vice President, Controller, effective December 6, 2021, and principal accounting officer, effective January 1, 2022.
Meridian Bioscience Announces Retirement of Chairman David Phillips
CINCINNATI, Nov. 24, 2021 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ:VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that David Phillips, Chairman of the Board of Directors, will retire from the Board of Directors and not seek re-election when his term ends in January 2022. The Board of Directors will elect a new chair when Mr. Phillips' term expires and will not replace the vacated seat, which will reduce the number of directors to eight. Mr. Phillips joined the Meridian Board of Directors in 2000 and ha
Meridian Bioscience Inc. Financials
Live finance-specific insights
Meridian Bioscience, Inc. Enters into Agreement to Be Acquired by SD Biosensor and SJL Partners in $1.53 Billion All-Cash Transaction
Shareholders to Receive $34.00 Per Share in Cash, Providing Immediate, Compelling and Certain Value Transaction Follows Deliberate Review, Including Outreach to Potential Strategic and Financial Partners CINCINNATI and SEOUL, South Korea, July 7, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. ("Meridian" or the "Company") (NASDAQ:VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, and SD Biosensor, Inc. ("SDB") (KOSE: A137310) and SJL Partners LLC ("SJL") (collectively, the "Consortium") announced today that they have entered into a definitive merger agreement whereby a newly formed affiliate vehicle of the Consortium will acquire Meridian in an a
MERIDIAN BIOSCIENCE REPORTS RECORD SECOND QUARTER FISCAL 2022 OPERATING RESULTS
CINCINNATI, May 6, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced financial results for the second quarter ended March 31, 2022. Second Quarter Fiscal 2022 Highlights (Comparison to Second Quarter Fiscal 2021): Consolidated net revenues totaled $111.2 million, the highest in Company history, with both segments ahead of expectationsLife Science segment delivered record net revenues of $70.1 millionDiagnostics segment net revenues increased 29% year-over-year to a record $41.1 millionLaunched Lyo-Ready™ sample specific master mixes for bloodResumed
Meridian Acquires EUPROTEIN to Further Expand Recombinant Protein Capabilities
CINCINNATI, Ohio, May 2, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ:VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that it has acquired, through its subsidiary Meridian Life Science, Inc., substantially all of the assets of EUPROTEIN Inc. The transaction closed on April 30, 2022. EUPROTEIN Inc. offers custom development and production of high-quality bioresearch reagents, with a particular focus on human and other mammalian proteins and recombinant monoclonal antibodies. This acquisition will help
Meridian Bioscience Announces Preliminary Net Revenues Results for Fiscal 2022 Second Quarter
CINCINNATI, April 7, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ:VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, today provided preliminary net revenues results for its second quarter of fiscal 2022. Preliminary unaudited net revenues for the second quarter of fiscal 2022 are expected to be between $109 million and $113 million, above Meridian's expectations and a record for the Company. Individually, both of the Company's segments are also expected to have record net revenues in the quarter with the Diagnostics segme
MERIDIAN BIOSCIENCE REPORTS SECOND BEST QUARTER IN COMPANY HISTORY
CINCINNATI, Feb. 4, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced financial results for the first quarter ended December 31, 2021. First Quarter Fiscal 2022 Highlights (Comparison to First Quarter Fiscal 2021): Consolidated net revenues of $88.3 million, second best in company history with both segments ahead of expectations Life Science segment delivered net revenues of $55.1 million Diagnostics segment net revenues increased 10% year-over-year to $33.2 million Launched first Lyo-Ready™ sample-specific master mix for saliva-based assays Receive
Meridian Bioscience to Hold First Quarter 2022 Financial Results Conference Call on February 4, 2022
CINCINNATI, Jan. 10, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ:VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, will report first quarter 2022 financial results Friday, February 4, 2022. Jack Kenny, Chief Executive Officer, will host a conference call beginning at 10:00 a.m. Eastern Time to discuss the results and answer questions. To participate in the live call by webcast, join directly here or visit investor.meridianbioscience.com for the link. If you are unable to join the webcast, you may join by telephone. Fr
Meridian Bioscience Reports Strong Fourth Quarter And Record Full-Year Fiscal 2021 Operating Results And Provides Fiscal 2022 Guidance
CINCINNATI, Nov. 12, 2021 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced financial results for the fourth quarter and fiscal year ended September 30, 2021. Fourth Quarter 2021 Highlights (Comparison to Fourth Quarter Fiscal 2020): Consolidated net revenues of $76.2 million, up 19% year-over-year Life Science segment delivered net revenues of $41.9 million, up 22% year-over-year Diagnostics segment net revenues increased 15% year-over-year to $34.3 million Launched Air-Dryable™ sample specific master mixes for stool, blood and urine and Air-Dryable™ LA
Meridian Bioscience to Hold Fourth Quarter and Full Year 2021 Financial Results Conference Call on November 12, 2021
CINCINNATI, Oct. 14, 2021 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ:VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, will report fourth quarter and full year 2021 financial results Friday, November 12, 2021. Jack Kenny, Chief Executive Officer, and Bryan Baldasare, Executive Vice President and Chief Financial Officer, will host a conference call beginning at 10:00 a.m. Eastern Time to discuss the results and answer questions. Meridian is introducing a live webcast for this and future earnings calls. This will provide
Meridian Bioscience Reports Third Quarter Fiscal 2021 Results
CINCINNATI, Aug. 06, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced financial results for the third quarter ended June 30, 2021. Third Quarter 2021 Highlights (Comparison to Third Quarter Fiscal 2020):• Consolidated net revenues of $63.5 million, down 25% year-over-year, but up 31% from pre-pandemic third quarter fiscal 2019• Diagnostics segment net revenues increased 44% year-over-year to $31.2 million• Life Science segment net revenues decreased 49% year-over-year to $32.3 million• Re-Submitted Emergency Use Authorization ("EUA") with U.S. Food and Drug Administration ("FDA") for Revogene® SARS-CoV-2 assay• Launched Lyo-Ready master mixes for loop-media
Meridian Bioscience Inc. Large Ownership Changes
This live feed shows all institutional transactions in real time.
SEC Form SC 13G/A filed by Meridian Bioscience Inc. (Amendment)
SC 13G/A - MERIDIAN BIOSCIENCE INC (0000794172) (Subject)
SEC Form SC 13D/A filed by Meridian Bioscience Inc. (Amendment)
SC 13D/A - MERIDIAN BIOSCIENCE INC (0000794172) (Subject)
SEC Form SC 13G/A filed by Meridian Bioscience Inc. (Amendment)
SC 13G/A - MERIDIAN BIOSCIENCE INC (0000794172) (Subject)
SEC Form SC 13D/A filed by Meridian Bioscience Inc. (Amendment)
SC 13D/A - MERIDIAN BIOSCIENCE INC (0000794172) (Subject)
SEC Form SC 13D/A filed by Meridian Bioscience Inc. (Amendment)
SC 13D/A - MERIDIAN BIOSCIENCE INC (0000794172) (Subject)
SEC Form SC 13D/A filed by Meridian Bioscience Inc. (Amendment)
SC 13D/A - MERIDIAN BIOSCIENCE INC (0000794172) (Subject)
SEC Form SC 13D/A filed by Meridian Bioscience Inc. (Amendment)
SC 13D/A - MERIDIAN BIOSCIENCE INC (0000794172) (Subject)
SEC Form SC 13D/A filed by Meridian Bioscience Inc. (Amendment)
SC 13D/A - MERIDIAN BIOSCIENCE INC (0000794172) (Subject)
SEC Form SC 13D/A filed by Meridian Bioscience Inc. (Amendment)
SC 13D/A - MERIDIAN BIOSCIENCE INC (0000794172) (Subject)
SEC Form SC 13D filed by Meridian Bioscience Inc.
SC 13D - MERIDIAN BIOSCIENCE INC (0000794172) (Subject)